Overexpression of microRNA-23a potentiated the response of HCC to the TOP2A targeted drugs etoposide and doxorubicin in vivo and in vitro, while suppressing another topoisomerase, TOP1, but not altering TOP2A expression levels [28]. This evidence concerns the gene TOP1 and hepatocellular carcinoma.